"Biphenyl Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Whitish aromatic crystalline organic compounds made up of two conjoined BENZENE rings.
| Descriptor ID |
D001713
|
| MeSH Number(s) |
D02.455.426.559.389.185
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Biphenyl Compounds".
Below are MeSH descriptors whose meaning is more specific than "Biphenyl Compounds".
This graph shows the total number of publications written about "Biphenyl Compounds" by people in this website by year, and whether "Biphenyl Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 0 | 1 |
| 2001 | 2 | 0 | 2 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 2 | 2 |
| 2006 | 2 | 0 | 2 |
| 2007 | 2 | 1 | 3 |
| 2008 | 1 | 4 | 5 |
| 2009 | 3 | 1 | 4 |
| 2010 | 1 | 2 | 3 |
| 2011 | 3 | 6 | 9 |
| 2012 | 0 | 2 | 2 |
| 2013 | 3 | 2 | 5 |
| 2014 | 3 | 6 | 9 |
| 2015 | 5 | 5 | 10 |
| 2016 | 5 | 1 | 6 |
| 2017 | 2 | 1 | 3 |
| 2018 | 2 | 1 | 3 |
| 2019 | 0 | 6 | 6 |
| 2020 | 1 | 9 | 10 |
| 2021 | 2 | 7 | 9 |
| 2022 | 0 | 2 | 2 |
| 2023 | 1 | 1 | 2 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Biphenyl Compounds" by people in Profiles.
-
The national financial burden of guideline directed medical therapy for heart failure patients from 2013 to 2021. Curr Probl Cardiol. 2024 Aug; 49(8):102684.
-
A retrospective analysis of the use of candesartan for migraine prevention in adolescents. Headache. 2024 01; 64(1):96-97.
-
Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma. Clin Lymphoma Myeloma Leuk. 2024 02; 24(2):105-121.
-
Concomitant medication use does not appear to alter long-term efficacy of sonidegib for advanced basal cell carcinoma: a post hoc analysis based on the 42-month BOLT study. Eur J Dermatol. 2023 Jun 01; 33(3):280-286.
-
Deciding Whether to Take Sacubitril/Valsartan: How Cardiologists and Patients Discuss Out-of-Pocket Costs. J Am Heart Assoc. 2023 04 04; 12(7):e028278.
-
Brequinar and dipyridamole in combination exhibits synergistic antiviral activity against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19. Antiviral Res. 2022 10; 206:105403.
-
The year in cardiovascular medicine 2021: heart failure and cardiomyopathies. Eur Heart J. 2022 Feb 03; 43(5):367-376.
-
Combination of Atezolizumab and Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results From a Phase Ib Study. Clin Lymphoma Myeloma Leuk. 2022 07; 22(7):504-512.
-
Evaluation of an EZH2 inhibitor in patient-derived orthotopic xenograft models of pediatric brain tumors alone and in combination with chemo- and radiation therapies. Lab Invest. 2022 02; 102(2):185-193.
-
Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. Circulation. 2022 01 04; 145(1):87-89.